Brought to you by 
Medicis licenses Corixa's PVAC in US, Canada
27 Dec 2003
Executive Summary
Medicis licensed exclusive marketing rights in the US and Canada to Corixa's PVAC, which is in Phase II trials to treat moderate to severe psoriasis.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medicis licenses Corixa's PVAC in US, Canada
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice